Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to 17.98%.

  • Exagen's EBIT Margin rose 193100.0% to 17.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.62%, marking a year-over-year increase of 80000.0%. This contributed to the annual value of 24.51% for FY2024, which is 189500.0% up from last year.
  • As of Q3 2025, Exagen's EBIT Margin stood at 17.98%, which was up 193100.0% from 15.29% recorded in Q2 2025.
  • In the past 5 years, Exagen's EBIT Margin ranged from a high of 15.29% in Q2 2025 and a low of 184.91% during Q2 2022
  • For the 5-year period, Exagen's EBIT Margin averaged around 51.45%, with its median value being 37.78% (2023).
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by -1399500bps in 2022, then surged by 1501400bps in 2023.
  • Quarter analysis of 5 years shows Exagen's EBIT Margin stood at 49.29% in 2021, then plummeted by -129bps to 112.88% in 2022, then skyrocketed by 67bps to 37.39% in 2023, then skyrocketed by 34bps to 24.77% in 2024, then increased by 27bps to 17.98% in 2025.
  • Its last three reported values are 17.98% in Q3 2025, 15.29% for Q2 2025, and 21.71% during Q1 2025.